Recurrent Tumor, continued

A Phase II Trial of EMD 121974 for Recurrent Glioblastoma: a Clinical Trial with Tissue Correlates of Response (NABTC 03-02)

A Phase II Trial of Poly ICLC in Patients with Recurrent Anaplastic Glioma (NABTC 01-06)

A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme that has Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection

A Phase II Trial of STI571 in Patients with Recurrent Meningioma (NABTC 01-08)

Phase II Trial of Convection-Enhanced Delivery (CED) of IL13-PE38QQR Cytotoxin After Resection and Prior to Radiation Therapy with or without Temozolomide in Patients with Newly Diagnosed Supratentorial Malignant Glioma

A Phase I/III Randomized Study of Radiation Therapy and Temozolomide vs Radiation Therapy and BCNU vs Radiation Therapy and Temozolomide and BCNU for Anaplastic Astrocytoma (RTOG 9813)

Phase III Randomized Evaluation of Convection-Enhanced Delivery of IL13-PEQQR Compared to Gliadel Wafer with Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence

A Phase II Trial of ST1571 in Patients with Recurrent Meningioma (NABTC 01-08)

Newly Diagnosed Malignant Glioma

Newly Diagnosed Low-Grade Glioma

A Phase I Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma

Recurrent Tumor

A Phase I/II Trial of Depsipeptide in Patients with Recurrent High-Grade Gliomas (NABTC 03-03)

A Phase I/II, Two-Arm, Multicenter, Dose-Escalation Study of Oral AEE788 Administered on a Continuous Once-Daily Dosing Schedule in Adult Patients with Recurrent or Relapsing Glioblastoma Multiforme

A Biomarker and Phase II Study of GW 572016 in Recurrent Malignant Glioma (NABTC 04-01)

Non-Chemotherapy Protocols

San Francisco Bay Area Adult Glioma Prognosis Study

A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas

Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for adults being performed through the North American Brain Tumor Consortium (NABTC), visit: <http://www.nabtc.org/>
Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for children being performed through the Pediatric Brain Tumor Consortium (PBTC), visit: <http://www.pbtc.org/>

Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors (PBTC 001)

This is a risk-adapted, multimodality trial for patients under the age of 3 years newly diagnosed with medulloblastoma/PNET, metastatic ependymoma, or other primary intracranial embryonal tumors. For further details: <http://www.pbtc.org/public/PBTC001_HP_abstract.htm>

Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors (PBTC 005)

This is a phase I trial for patients with recurrent or refractory pediatric brain tumors. For further details: <http://www.pbtc.org/public/PBTC005_HP_abstract.htm>

A Phase I/II Trial of ZD1839 (Iressa™) and Radiation in Pediatric Patients Newly Diagnosed with Brainstem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II Limited to Brainstem Tumors (PBTC 007)

Children with newly diagnosed intrinsic brainstem gliomas and incompletely resected supratentorial malignant gliomas with residual tumor on imaging will be eligible for this study. For further details: <http://www.pbtc.org/public/PBTC007_HP_abstract.htm>

Phase I/II Trial of R115777 and Radiation Therapy in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas (PBTC 014)

Children with newly diagnosed, diffuse, intrinsic pontine gliomas will be eligible for this study. Patients are to receive R115777 concurrently with radiation therapy and subsequent to radiation in the absence of dose-limiting toxicity or disease progression. For further details: <http://www.pbtc.org/public/PBTC014%20Protocol%20Abstract.pdf>

A Phase I Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma, or Ependymoma (PBTC 016)

Children with recurrent or refractory malignant central nervous system (CNS) tumors will be eligible for this study. A histological diagnosis of malignant CNS tumor from either the initial presentation or the time of recurrence is required for all patients except those with diffuse intrinsic brain stem gliomas. For further details: <http://www.pbtc.org/public/PBTC016%20Protocol%20Abstract.pdf>

For further details about clinical trials for children being performed at UCSF, visit <http://www.cc.ucsf.edu/>